Registrant’s telephone number, including area code: (281) 272-9331
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On the same day, members of the Company’s management will hold a teleconference to discuss the financial results and provide a corporate update. Interested individuals desiring to participate in the teleconference may dial in before the scheduled 4:30 P.M. ET call to (201) 689-8040 or toll free at (877) 407-8133. Please reference conference ID # 13642247 or the
Opexa Therapeutics Earnings Call when dialing into the call. A live webcast of the call can also be accessed via the webcast link on the Investor Relations page of the Company’s website (www.opexatherapeutics.com). An archive of the webcast will be available on the Company’s website until November 11, 2016.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities under that Section, nor be deemed to be incorporated by reference into the filings of the registrant under the
Securities Act of 1933.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.